Trial comparisons

curl "https://conductscience.org/api/comparisons/v1?page=119"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=119

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00312208-f73a5fb6",
        "title": "Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) vs Docetaxel + Doxorubicin and Cyclophosphamide (TAC): Death From Any Cause (Overall Survival)",
        "summary": "187 of 1649 against 202 of 1649; risk difference -0.9 points, 95% interval -3.1 to 1.3; NCT00312208, Docetaxel in Breast Cancer",
        "record": "/library/comparisons/NCT00312208-f73a5fb6",
        "nct_id": "NCT00312208",
        "kind": "outcome",
        "participants": 3298,
        "risk_difference": {
          "value": -0.009096422073984228,
          "lower": -0.031162673666971907,
          "upper": 0.012958015905097924
        },
        "group_1": "187 of 1,649",
        "group_2": "202 of 1,649",
        "difference": "-0.9 points",
        "interval": "-3.1 to 1.3",
        "trial_title": "Docetaxel in Breast Cancer"
      },
      {
        "id": "NCT01352845-sae",
        "title": "Group 1 rLP2086 vs Group 2 Saline: serious adverse events",
        "summary": "33 of 2471 against 11 of 822; risk difference -0.0 points, 95% interval -1.1 to 0.8; NCT01352845, A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.",
        "record": "/library/comparisons/NCT01352845-sae",
        "nct_id": "NCT01352845",
        "kind": "serious-adverse-events",
        "participants": 3293,
        "risk_difference": {
          "value": -0.00002707809618336665,
          "lower": -0.011129155741582934,
          "upper": 0.007926199721466975
        },
        "group_1": "33 of 2,471",
        "group_2": "11 of 822",
        "difference": "-0.0 points",
        "interval": "-1.1 to 0.8",
        "trial_title": "A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years."
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=120",
  "request_id": "ZVnjFZYhpXXTidcP"
}